Aberrant Activation of TGF-β in Subchondral Bone at the Onset of Rheumatoid Arthritis Joint Destruction

Journal of Bone and Mineral Research

Volumn 30, Issue 11, 2015, Pages 2033-2043

  Xu, Xin ^a,b   Zheng, Liwei ^a,b   Bian, Qin ^b,c   Xie, Liang ^a,b   Liu, Wenlong ^b,d   Zhen, Gehua ^b   Crane, Janet L ^b   Zhou, Xuedong ^a   Cao, Xu ^b  

^a SICHUAN UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CARTILAGE DEGENERATION; MESENCHYMAL STEM CELLS; RHEUMATOID ARTHRITIS; SUBCHONDRAL BONE; TGF

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; NESTIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; COLLAGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; ARTICULAR CARTILAGE; BONE DEVELOPMENT; BONE MARROW; BONE MASS; BONE TISSUE; CARTILAGE DEGENERATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE COURSE; GENE INACTIVATION; IMMUNE RESPONSE; IN VIVO STUDY; JOINT DESTRUCTION; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SUBCHONDRAL BONE; SUBCHONDRAL BONE PLATE; TIBIA EPIPHYSIS; TRABECULAR BONE; ANIMAL; BONE; C57BL MOUSE; DISEASE MODEL; JOINT; KNOCKOUT MOUSE; LEWIS RAT; METABOLISM; PATHOLOGY; SERODIAGNOSIS; SIGNAL TRANSDUCTION; TIBIA;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE MARROW; BONE RESORPTION; CARTILAGE, ARTICULAR; COLLAGEN; DISEASE MODELS, ANIMAL; JOINTS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; NESTIN; NEUTRALIZATION TESTS; OSTEOGENESIS; RATS, INBRED LEW; SIGNAL TRANSDUCTION; TIBIA; TRANSFORMING GROWTH FACTOR BETA;

EID: 84945481472     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2550     Document Type: Article

References (49)

1. McInnes IB, Schett G., Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007; 7 (6): 429-42.
2. Schuerwegh AJ, Dombrecht EJ, Stevens WJ, Van Offel JF, Bridts CH, De Clerck LS., Influence of pro-inflammatory (IL-1 alpha, IL-6, TNF-alpha, IFN-gamma) and anti-inflammatory (IL-4) cytokines on chondrocyte function. Osteoarthritis Cartilage. 2003; 11 (9): 681-7.
3. van den Berg WB, McInnes IB., Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum. 2013; 43 (2): 158-70.
4. Verstappen SM., Outcomes of early rheumatoid arthritis-the WHO ICF framework. Best Pract Res Clin Rheumatol. 2013; 27 (4): 555-70.
5. Scott DL, Wolfe F, Huizinga TW., Rheumatoid arthritis. Lancet. 2010; 376 (9746): 1094-108.
6. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T., The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol. 2007; 36 (6): 411-7.
7. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A., Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta-analysis of efficacy and safety. BMC Musculoskelet Disord. 2008; 9: 52.
8. Singh JA, Christensen R, Wells GA, et al., A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009; 181 (11): 787-96.
9. Singh JA, Christensen R, Wells GA, et al., Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 (4): CD007848.
10. Maxwell LJ, Singh JA., Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2010; 37 (2): 234-45.
11. Vivar N, Van Vollenhoven RF., Advances in the treatment of rheumatoid arthritis. F1000Prime Rep. 2014; 6: 31.
12. Imhof H, Sulzbacher I, Grampp S, Czerny C, Youssefzadeh S, Kainberger F., Subchondral bone and cartilage disease: a rediscovered functional unit. Invest Radiol. 2000; 35 (10): 581-8.
13. Schett G, Firestein GS., Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis. Ann Rheum Dis. 2010; 69 (5): 787-9.
14. Burr DB, Gallant MA., Bone remodelling in osteoarthritis. Nat Rev Rheumatol. 2012; 8 (11): 665-73.
15. Hetland ML, Ejbjerg B, Horslev-Petersen K, et al., MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis. 2009; 68 (3): 384-90.
16. Haavardsholm EA, Boyesen P, Ostergaard M, Schildvold A, Kvien TK., Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis. 2008; 67 (6): 794-800.
17. McQueen FM, Benton N, Perry D, et al., Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum. 2003; 48 (7): 1814-27.
18. Cohen SB, Dore RK, Lane NE, et al., Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008; 58 (5): 1299-309.
19. Zhen G, Wen C, Jia X, et al., Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 2013; 19 (6): 704-12.
20. Redlich K, Smolen JS., Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012; 11 (3): 234-50.
21. Walsh NC, Gravallese EM., Bone remodeling in rheumatic disease: a question of balance. Immunol Rev. 2010; 233 (1): 301-12.
22. Tang Y, Wu X, Lei W, et al., TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15 (7): 757-65.
23. Sakuma M, Hatsushika K, Koyama K, et al., TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. 2007; 19 (2): 117-26.
24. Wahl SM, Allen JB, Costa GL, Wong HL, Dasch JR., Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J Exp Med. 1993; 177 (1): 225-30.
25. Gao P, Zhou Y, Xian L, et al., Functional effects of TGF-beta1 on mesenchymal stem cell mobilization in cockroach allergen-induced asthma. J Immunol. 2014; 192 (10): 4560-70.
26. Brand DD, Latham KA, Rosloniec EF., Collagen-induced arthritis. Nat Protoc. 2007; 2 (5): 1269-75.
27. Wagner S, Bindler J, Andriambeloson E., Unit 5.51: animal models of collagen-induced arthritis. Curr Protoc Pharmacol. 2008 Dec;Chapter 5:Unit 5.51. DOI: 10.1002/0471141755.ph0551s43
28. Brenet F, Kermani P, Spektor R, Rafii S, Scandura JM., TGFbeta restores hematopoietic homeostasis after myelosuppressive chemotherapy. J Exp Med. 2013; 210 (3): 623-39.
29. Proulx ST, Kwok E, You Z, et al., Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 2008; 58 (7): 2019-29.
30. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25 (7): 1468-86.
31. Wu X, Pang L, Lei W, et al., Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell. 2010; 7 (5): 571-80.
32. Grafe I, Yang T, Alexander S, et al., Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta. Nat Med. 2014; 20 (6): 670-5.
33. Border WA, Noble NA., Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994; 331 (19): 1286-92.
34. Blobe GC, Schiemann WP, Lodish HF., Role of transforming growth factor beta in human disease. N Engl J Med. 2000; 342 (18): 1350-8.
35. Elliott RL, Blobe GC., Role of transforming growth factor Beta in human cancer. J Clin Oncol. 2005; 23 (9): 2078-93.
36. Lamouille S, Xu J, Derynck R., Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15 (3): 178-96.
37. Shen J, Li S, Chen D., TGF-β signaling and the development of osteoarthritis. Bone Res. 2014; 2: 14002. DOI: 10.1038/boneres.2014.2
38. Bush JR, Beier F., TGF-beta and osteoarthritis-the good and the bad. Nat Med. 2013; 19 (6): 667-9.
39. Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B, et al., Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum. 2007; 56 (4): 1118-24.
40. Olech E, Crues JV 3rd, Yocum DE, Merrill JT., Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on noncontrast magnetic resonance imaging of the hands and wrists: a comparison of patients with RA and healthy controls. J Rheumatol. 2010; 37 (2): 265-74.
41. Roemer FW, Guermazi A, Javaid MK, et al., Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: the MOST Study. A longitudinal multicentre study of knee osteoarthritis. Ann Rheum Dis. 2009; 68 (9): 1461-5.
42. Sharkey PF, Cohen SB, Leinberry CF, Parvizi J., Subchondral bone marrow lesions associated with knee osteoarthritis. Am J Orthop (Belle Mead NJ). 2012; 41 (9): 413-7.
43. Loeuille D, Chary-Valckenaere I., MRI in OA: from cartilage to bone marrow lesion. Osteoporos Int. 2012; 23 Suppl 8: S867-9.
44. Walsh NC, Reinwald S, Manning CA, et al., Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009; 24 (9): 1572-85.
45. Zhang H, Hilton MJ, Anolik JH, et al., NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-kappaB. J Clin Invest. 2014; 124 (7): 3200-14.
46. Li G, Ma Y, Cheng TS, et al., Identical subchondral bone microarchitecture pattern with increased bone resorption observed in rheumatoid arthritis as compared to osteoarthritis. Osteoarthritis Cartilage. 2014; 22 (12): 2083-92. DOI: 10.1016/j.joca.2014.08.015
47. Mizoguchi T, Pinho S, Ahmed J, et al., Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. Dev Cell. 2014; 29 (3): 340-9.
48. Ono N, Ono W, Mizoguchi T, Nagasawa T, Frenette PS, Kronenberg HM., Vasculature-associated cells expressing nestin in developing bones encompass early cells in the osteoblast and endothelial lineage. Dev Cell. 2014; 29 (3): 330-9.
49. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ., Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell. 2014; 15 (2): 154-68.